1-(2-呋喃基)哌嗪 | 212897-82-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(2-呋喃基)哌嗪
• 英文名称: 1-(2-furyl)piperazine
• 英文别名: 1-(furan-2-yl)piperazine；N-2-furylpiperazine；N-2-furanyl-piperazine
• CAS: 212897-82-0
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: CYNXYQWCYHOAOY-UHFFFAOYSA-N

物化性质

• 沸点：
  262.4±20.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-呋喃基)哌嗪 、 4-Chlor-2-methyl-6-methylthio-7H-pyrrolo<2.3-d>pyrimidin-5-carbonitril 以 乙醇 为溶剂， 以62%的产率得到4-<4-(Furo-2-yl)-piperazin-1-yl>-2-methyl-6-methylthio-7H-pyrrolo<2.3-d>pyrimidin-5-carbonitril
  参考文献：
  名称：

  Pech, Reinhard; Boehm, Ralf; Henkel, Lutz, Zeitschrift fur Chemie, 1990, vol. 30, # 7, p. 248 - 249

  摘要：

  DOI：

文献信息

• Benzene sulfonamides as PDE-V inhibitors for the use against erectile dysfunction
  申请人：The Jordanian Pharmaceutical Manufacturing and Medical Equipment Co.Ltd.

  公开号：EP1219614A9

  公开（公告）日：2003-01-02

  The compounds of formula (I) wherein X, R0, R1, R2, n and m have the meanings given in the specification, are useful as active ingredients in pharmaceutical compositions. The invention relates to the use of said compounds as a medicament and for the manufacture of a medicament for the treatment of erectile dysfunction.

  式（I）中X，R0，R1，R2，n和m的化合物具有规范中给定的含义，可用作药物组合物中的活性成分。本发明涉及将上述化合物用作药物和用于制造治疗勃起功能障碍的药物的用途。
• Synthesis and Antibacterial Evaluation of Mannich Bases Derived from 1,2,4‐Triazole
  作者：Agata Paneth、Nazar Trotsko、Łukasz Popiołek、Agnieszka Grzegorczyk、Tomasz Krzanowski、Sara Janowska、Anna Malm、Monika Wujec

  DOI：10.1002/cbdv.201900377

  日期：2019.10

  The series of novel Mannich bases were synthesized and evaluated for their in vitro antibacterial activity against Gram-positive and Gram-negative bacterial strains. The results showed that all compounds were less active than the drugs used as reference, but some of them had moderate potency against Staphylococcus epidermidis ATCC 12228 and Bacillus subtilis ATCC 6633. The presence of a phenyl ring

  合成了一系列新型曼尼希碱，并评估了它们对革兰氏阳性和革兰氏阴性细菌菌株的体外抗菌活性。结果表明，所有化合物的活性均低于用作参考药物的活性，但其中一些对表皮葡萄球菌ATCC 12228和枯草芽孢杆菌ATCC 6633具有中等效力。哌嗪4位上存在苯环似乎是必要的在这类化合物中具有抗菌活性。
• 异丙醇胺取代β-榄香烯衍生物及其制备方法 和用途
  申请人：石药集团远大（大连）制药有限公司

  公开号：CN106928074B

  公开（公告）日：2018-12-18

  本发明涉及异丙醇胺取代β‑榄香烯衍生物、其制备方法以及其用途，具体的，本发明涉及一种通式(I)或(II)所示的新的异丙醇胺取代β‑榄香烯衍生物、其制备方法及其在制备抗肿瘤药物方面的用途。
• Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
  申请人：Sircar Jagadish

  公开号：US20060229314A1

  公开（公告）日：2006-10-12

  Inhibitors of macrophage migration inhibitory factor having a thienopyridinone backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with macrophage migration inhibitory factor activity. The inhibitors of macrophage migration inhibitory factor have the following structures: including forms such as stereoisomers, free forms, pharmaceutically acceptable salts or esters thereof, solvates, or combinations of such forms, wherein n, R 1 , R 2 , R 3 , X, and Y are as defined herein. Compositions comprising an inhibitor of macrophage migration inhibitory factor in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了具有噻吩并吡啶骨架的巨噬细胞迁移抑制因子抑制剂，其在治疗多种疾病中具有用途，包括治疗与巨噬细胞迁移抑制因子活性相关的病理条件。巨噬细胞迁移抑制因子的抑制剂具有以下结构：包括立体异构体、自由形态、药学上可接受的盐或酯、溶剂化物或这些形式的组合，其中n、R1、R2、R3、X和Y如本文所定义。还提供了包含巨噬细胞迁移抑制因子抑制剂与药学上可接受的载体组合的组合物，以及使用它们的方法。
• THIENOPYRIDINONE DERIVATIVES AS MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITORS
  申请人：Sircar Jagadish

  公开号：US20070179149A1

  公开（公告）日：2007-08-02

  Inhibitors of macrophage migration inhibitory factor having a thienopyridinone backbone are provided which have utility in the treatment of a variety of disorders, including the treatment of pathological conditions associated with macrophage migration inhibitory factor activity. The inhibitors of macrophage migration inhibitory factor have the following structures: including forms such as stereoisomers, free forms, pharmaceutically acceptable salts or esters thereof, solvates, or combinations of such forms, wherein n, R 1 , R 2 , R 3 , X, and Y are as defined herein. Compositions comprising an inhibitor of macrophage migration inhibitory factor in combination with a pharmaceutically acceptable carrier are also provided, as well as methods for use of the same.

  提供了具有噻唑吡啶骨架的巨噬细胞迁移抑制因子抑制剂，其在治疗各种疾病中具有用途，包括与巨噬细胞迁移抑制因子活性相关的病理条件的治疗。巨噬细胞迁移抑制因子的抑制剂具有以下结构：包括立体异构体、自由形式、药学上可接受的盐或酯、溶剂化合物或这些形式的组合，其中n、R1、R2、R3、X和Y的定义如此处所述。还提供了包含巨噬细胞迁移抑制因子抑制剂与药学上可接受的载体组合的组合物，以及使用它们的方法。